StageZero Life Sciences Ltd.
SZLSF
$0.0021
-$0.025-92.25%
| 09/30/2024 | 06/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 28.10% | -25.25% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 28.10% | -25.25% | |||
| Cost of Revenue | 59.27% | 72.67% | |||
| Gross Profit | -1,500.00% | -97.40% | |||
| SG&A Expenses | -65.45% | 17.95% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -21.52% | 32.77% | |||
| Operating Income | 49.36% | -135.22% | |||
| Income Before Tax | 38.52% | -68.13% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 38.52% | -68.13% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 38.52% | -68.13% | |||
| EBIT | 49.36% | -135.22% | |||
| EBITDA | 48.27% | -134.94% | |||
| EPS Basic | 39.62% | -70.97% | |||
| Normalized Basic EPS | 39.39% | -65.00% | |||
| EPS Diluted | 39.62% | -70.97% | |||
| Normalized Diluted EPS | 39.39% | -65.00% | |||
| Average Basic Shares Outstanding | 0.00% | -0.02% | |||
| Average Diluted Shares Outstanding | 0.00% | -0.02% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
